NCT01357668 is a clinical trial in Juvenile Idiopathic Arthritis, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT01357668?

NCT01357668 is sponsored by Bristol-Myers Squibb.

What condition does NCT01357668 study?

NCT01357668 studies Juvenile Idiopathic Arthritis.

Is NCT01357668 still recruiting?

NCT01357668 is currently active, enrolled. Last updated 25 September 2025.

Last reviewed 2025-09-25 · How we verify

NCT01357668

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Active, enrolled Last updated 25 September 2025

What this trial tests

trial in Juvenile Idiopathic Arthritis in 800 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 January 2013

Primary endpoint
2 January 2029

2 January 2029

Quick facts

Lead sponsor	Bristol-Myers Squibb
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	800
Start date	30 January 2013
Primary completion	2 January 2029
Estimated completion	2 January 2029
Sites	59 locations across Italy, Denmark, Netherlands, Russia, Mexico, Portugal, United States, Latvia

Conditions studied

Juvenile Idiopathic Arthritis — all drugs for Juvenile Idiopathic Arthritis →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Under 17, any sex, with Juvenile Idiopathic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Using registries to identify adverse events in rheumatic diseases.
Lionetti G, Kimura Y, Schanberg LE, Beukelman T, et al · · 2013 · cited 18× · PMID 24144710 · DOI 10.1542/peds.2013-0755
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry.
Lovell DJ, Tzaribachev N, Henrickson M, Simonini G, et al · · 2024 · cited 10× · PMID 38243722 · DOI 10.1093/rheumatology/keae025
Proceedings of the 32nd European Paediatric Rheumatology Congress.
· 2025 · cited 1× · PMID 40958115 · DOI 10.1186/s12969-025-01138-8
Proceedings of the 26th European Paediatric Rheumatology Congress: part 1 : Virtual. 23 - 26 September 2020
· 2020

Verify or expand the search:

Other recruiting trials for Juvenile Idiopathic Arthritis

Currently open trials in the same condition.

NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT05879419 — Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases · Phase 4 · active not recruiting
NCT06007456 — Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis · recruiting
NCT03913962 — Health and Exercise Response in Children With Chronic and Auto-immune Pathologies · NA · recruiting
NCT06560606 — UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01357668 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 25 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01357668.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing